OTP Bank Reports Record Q3 2024 Net Profit of HUF 418bn, Beats Consensus by 12%

OTP Bank posted its strongest quarterly result in the group's history, driven by margin expansion and higher fee income across CEE subsidiaries.

Erste Group Research Upgrades OTP Bank to Buy, Raises Target Price to HUF 22,500

Erste analysts cite stronger-than-expected NIM trajectory and CEE franchise value as the basis for the upgrade, implying 22% upside from current levels.

MOL Group Q3 EBITDA Falls 18% as Refining Margins Compress; Downstream Drag Continues

MOL reported a weaker-than-expected Q3 result as European crack spreads contracted sharply. Upstream production growth provides partial offset.

Gedeon Richter Expands US Biosimilar Pipeline, Files cariprazine NDA Extension

Richter filed an NDA extension for cariprazine (Reagila/Vraylar) in a new indication, while announcing two additional biosimilar development agreements with US partners.

Magyar Telekom to Accelerate 5G Rollout; Plans 80% Population Coverage by End-2025

MTE announced an accelerated 5G network expansion programme, targeting nationwide urban coverage by mid-2025 and committing HUF 95bn in capex for FY 2025.

Hungarian Industrial Output Contracts 4.2% YoY in September; Construction Activity Weakest Since 2020

KSH data showed broad-based industrial weakness in September, with construction activity declining sharply. Affects OPUS Global's project pipeline outlook.

MNB Raises Systemic Buffer Requirement for OTP to 2.0%; Bank Comfortably Compliant

The Magyar Nemzeti Bank increased the Other Systemically Important Institution (O-SII) buffer for OTP from 1.5% to 2.0%, effective January 2026. OTP's current CET1 leaves ample headroom.

Richter Q3 2024 Revenue Up 11% to HUF 182bn; Operating Margin Expands to 24.3%

Gedeon Richter delivered solid Q3 results with double-digit revenue growth and significant margin improvement, driven by cariprazine royalties and biosimilar launches.